Study reveals low adoption of recommended smart inhaler therapy for asthma

FHS
May 22, 2024
3:51 am

Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen and over 40 percent of academic pulmonary and allergy clinicians have not adopted this optimal therapy, according to research published at the ATS 2024 International Conference.

Lilly partners with Haya for lncRNA obesity target deal worth $1bn – Pharmaceutical Technology

Eli Lilly and Haya Therapeutics aim to find multiple regulatory genome derived RNA-based drug targets for obesity. Credit: eamesBot via Shutterstock. Pharma giant Eli Lilly

September 5, 2024

Roche says it is undeterred by upcoming biosimilar threat to Vabysmo

Roche’s competition in the eye disease space is intensifying with Regeneron’s high-dose Eylea and a looming biosimilar challenge, but the Swiss pharma said its blockbuster

October 24, 2024

Real-time vital signs data: a hidden source of value in medical AI

If data represents the next gold rush for health care, a vast treasure trove of it slips away every day. The increased enthusiasm for AI

July 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.